{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:29Z","timestamp":1792783409003,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pfizer, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40121-024-01064-4","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:41:35Z","timestamp":1729730495000},"page":"2527-2543","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effectiveness, Safety, and Patterns of Real-World Isavuconazole Use in Europe (2015\u20132019)"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct04550936","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Dionysios","family":"Neofytos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pagliuca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4416-6080","authenticated-orcid":false,"given":"Katherine","family":"Houghton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Broughton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Lavinea Novis","family":"de Figueiredo Valente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Enoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Gruener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul","family":"Herbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Lahmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9a","family":"Melenotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Giuseppe","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Garcia-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"key":"1064_CR1","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1055\/s-0035-1562893","volume":"36","author":"KS Gregg","year":"2015","unstructured":"Gregg KS, Kauffman CA. Invasive aspergillosis: epidemiology, clinical aspects, and treatment. presented at the Seminars in respiratory and critical care medicine. Semin Respir Crit Care Med. 2015;36:662\u201372.","journal-title":"Semin Respir Crit Care Med"},{"key":"1064_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2022.08.004","author":"X Cui","year":"2022","unstructured":"Cui X, Wang L, L\u00fc Y, Yue C. Development and research progress of anti-drug resistant fungal drugs. J Infect Public Health. 2022. https:\/\/doi.org\/10.1016\/j.jiph.2022.08.004.","journal-title":"J Infect Public Health"},{"issue":"17","key":"1064_CR3","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","volume":"131","author":"D Ghez","year":"2018","unstructured":"Ghez D, Calleja A, Protin C, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131(17):1955\u20139.","journal-title":"Blood"},{"issue":"1","key":"1064_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jhin.2018.12.020","volume":"103","author":"A Talento","year":"2019","unstructured":"Talento A, Fitzgerald M, Redington B, O\u2019Sullivan N, Fenelon L, Rogers T. Prevention of healthcare-associated invasive aspergillosis during hospital construction\/renovation works. J Hosp Infect. 2019;103(1):1\u201312.","journal-title":"J Hosp Infect"},{"issue":"Suppl 1","key":"1064_CR5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","volume":"24","author":"AJ Ullmann","year":"2018","unstructured":"Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1\u201338. https:\/\/doi.org\/10.1016\/j.cmi.2018.01.002.","journal-title":"Clin Microbiol Infect"},{"issue":"10020","key":"1064_CR6","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","volume":"387","author":"JA Maertens","year":"2016","unstructured":"Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760\u20139.","journal-title":"Lancet"},{"issue":"7","key":"1064_CR7","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","volume":"16","author":"FM Marty","year":"2016","unstructured":"Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828\u201337. https:\/\/doi.org\/10.1016\/S1473-3099(16)00071-2.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"1064_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/jof8010074","volume":"8","author":"H Dagher","year":"2022","unstructured":"Dagher H, Hachem R, Chaftari A-M, et al. Real-world use of isavuconazole as primary therapy for invasive fungal infections in high-risk patients with hematologic malignancy or stem cell transplant. J Fungi. 2022;8(1):74.","journal-title":"J Fungi"},{"issue":"6","key":"1064_CR9","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/myc.12910","volume":"62","author":"H Hassouna","year":"2019","unstructured":"Hassouna H, Athans V, Brizendine KD. Real-world use\u2014Isavuconazole at a large academic medical center. Mycoses. 2019;62(6):534\u201341.","journal-title":"Mycoses"},{"issue":"6","key":"1064_CR10","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s11046-021-00583-9","volume":"186","author":"I Kronig","year":"2021","unstructured":"Kronig I, Masouridi-Levrat S, Chalandon Y, et al. Clinical considerations of isavuconazole administration in high-risk hematological patients: a single-center 5-year experience. Mycopathologia. 2021;186(6):775\u201388.","journal-title":"Mycopathologia"},{"issue":"2","key":"1064_CR11","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/jof9020166","volume":"9","author":"MV Batista","year":"2023","unstructured":"Batista MV, Ussetti MP, Jiang Y, et al. Comparing the real-world use of isavuconazole to other anti-fungal therapy for invasive fungal infections in patients with and without underlying disparities: a multi-center retrospective study. J Fungi. 2023;9(2):166.","journal-title":"J Fungi"},{"issue":"3","key":"1064_CR12","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1097\/TP.0000000000004312","volume":"107","author":"M Fern\u00e1ndez-Ruiz","year":"2023","unstructured":"Fern\u00e1ndez-Ruiz M, Bodro M, Mart\u00edn IG, et al. Isavuconazole for the treatment of invasive mold disease in solid organ transplant recipients: a multicenter study on efficacy and safety in real-life clinical practice. Transplantation. 2023;107(3):762\u201373. https:\/\/doi.org\/10.1097\/TP.0000000000004312.","journal-title":"Transplantation"},{"issue":"12","key":"1064_CR13","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B De Pauw","year":"2008","unstructured":"De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) consensus group. Clin Infect Dis. 2008;46(12):1813\u201321.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1064_CR14","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jinf.2018.02.012","volume":"76","author":"RJ van de Peppel","year":"2018","unstructured":"van de Peppel RJ, Visser L, Dekkers O, de Boer MG. The burden of invasive aspergillosis in patients with haematological malignancy: a meta-analysis and systematic review. J Infect. 2018;76(6):550\u201362.","journal-title":"J Infect"},{"issue":"8","key":"1064_CR15","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1080\/17474086.2020.1796624","volume":"13","author":"L Pagano","year":"2020","unstructured":"Pagano L, Dragonetti G, De Carolis E, Veltri G, Del Principe MI, Busca A. Developments in identifying and managing mucormycosis in hematologic cancer patients. Expert Rev Hematol. 2020;13(8):895\u2013905.","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"1064_CR16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3390\/jof6040265","volume":"6","author":"A Skiada","year":"2020","unstructured":"Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: an update. J Fungi. 2020;6(4):265.","journal-title":"J Fungi"},{"issue":"8","key":"1064_CR17","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/myc.12927","volume":"62","author":"EE Tejerina","year":"2019","unstructured":"Tejerina EE, Abril E, Padilla R, et al. Invasive aspergillosis in critically ill patients: an autopsy study. Mycoses. 2019;62(8):673\u20139.","journal-title":"Mycoses"},{"issue":"3","key":"1064_CR18","doi-asserted-by":"publisher","first-page":"myad0021","DOI":"10.1093\/mmy\/myad021","volume":"61","author":"P Monz\u00f3-Gallo","year":"2023","unstructured":"Monz\u00f3-Gallo P, Chumbita M, Lopera C, et al. Real-life epidemiology and current outcomes of hospitalized adults with invasive fungal infections. Med Mycol. 2023;61(3):myad0021.","journal-title":"Med Mycol"},{"issue":"2","key":"1064_CR19","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1093\/mmy\/myy081","volume":"57","author":"F Danion","year":"2019","unstructured":"Danion F, Rouzaud C, Dur\u00e9ault A, et al. Why are so many cases of invasive aspergillosis missed? Med Mycol J. 2019;57(2):S94\u2013103.","journal-title":"Med Mycol J"},{"issue":"11","key":"1064_CR20","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.3390\/diagnostics12112712","volume":"12","author":"L Townsend","year":"2022","unstructured":"Townsend L, Martin-Loeches I. Invasive aspergillosis in the intensive care unit. Diagnostics. 2022;12(11):2712.","journal-title":"Diagnostics"},{"issue":"10","key":"1064_CR21","doi-asserted-by":"publisher","first-page":"5563","DOI":"10.3390\/ijms23105563","volume":"23","author":"X Lian","year":"2022","unstructured":"Lian X, Scott-Thomas A, Lewis JG, et al. Monoclonal antibodies and invasive aspergillosis: diagnostic and therapeutic perspectives. Int J Mol Sci. 2022;23(10):5563.","journal-title":"Int J Mol Sci"},{"key":"1064_CR22","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.12688\/f1000research.15081.1","volume":"7","author":"B Pilmis","year":"2018","unstructured":"Pilmis B, Alanio A, Lortholary O, Lanternier F. Recent advances in the understanding and management of mucormycosis. F1000Research. 2018;7:1429.","journal-title":"F1000Research"},{"issue":"5","key":"1064_CR23","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/cid\/ciab1066","volume":"75","author":"L Millon","year":"2022","unstructured":"Millon L, Caillot D, Berceanu A, et al. Evaluation of serum Mucorales polymerase chain reaction (PCR) for the diagnosis of mucormycoses: the MODIMUCOR prospective trial. Clin Infect Dis. 2022;75(5):777\u201385.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1064_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/myc.13416","volume":"65","author":"RS Roth","year":"2022","unstructured":"Roth RS, Masouridi-Levrat S, Giannotti F, et al. Frequency and causes of antifungal treatment changes in allogeneic haematopo\u00efetic cell transplant recipients with invasive mould infections. Mycoses. 2022;65(2):199\u2013210.","journal-title":"Mycoses"},{"key":"1064_CR25","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.2147\/IDR.S372546","volume":"16","author":"M Egger","year":"2023","unstructured":"Egger M, Bellmann R, Krause R, Boyer J, Jak\u0161i\u0107 D, Hoenigl M. Salvage treatment for invasive aspergillosis and mucormycosis: challenges, recommendations and future considerations. Infect Drug Resist. 2023;16:2167\u201378.","journal-title":"Infect Drug Resist"},{"issue":"12","key":"1064_CR26","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","volume":"19","author":"OA Cornely","year":"2019","unstructured":"Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405\u201321.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"1064_CR27","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1093\/cid\/ciy473","volume":"67","author":"MS Lionakis","year":"2018","unstructured":"Lionakis MS, Lewis RE, Kontoyiannis DP. Breakthrough invasive mold infections in the hematology patient: current concepts and future directions. Clin Infect Dis. 2018;67(10):1621\u201330.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1064_CR28","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3390\/jof8040362","volume":"8","author":"L Nwankwo","year":"2022","unstructured":"Nwankwo L, Gilmartin D, Matharu S, et al. Experience of isavuconazole as a salvage therapy in chronic pulmonary fungal disease. J Fungi. 2022;8(4):362.","journal-title":"J Fungi"},{"issue":"6","key":"1064_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000320","volume":"3","author":"C Cattaneo","year":"2019","unstructured":"Cattaneo C, Gramegna D, Farina F, et al. Isavuconazole in hematological patients: results of a real-life multicentre observational Seifem study. HemaSphere. 2019;3(6): e320. https:\/\/doi.org\/10.1097\/HS9.0000000000000320.","journal-title":"HemaSphere"},{"issue":"5","key":"1064_CR30","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/myc.13567","volume":"66","author":"J Jeck","year":"2023","unstructured":"Jeck J, Wingen-Heimann SM, Jakobs F, et al. Health economic analysis of patients treated with isavuconazole in a German comprehensive cancer centre. Mycoses. 2023;66(5):405\u201311. https:\/\/doi.org\/10.1111\/myc.13567.","journal-title":"Mycoses"},{"issue":"4","key":"1064_CR31","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s40121-022-00661-5","volume":"11","author":"L Ostrosky-Zeichner","year":"2022","unstructured":"Ostrosky-Zeichner L, Nguyen MH, Bubalo J, et al. Multicenter registry of patients receiving systemic mold-active triazoles for the management of invasive fungal infections. Infect Dis Ther. 2022;11(4):1609\u201329. https:\/\/doi.org\/10.1007\/s40121-022-00661-5.","journal-title":"Infect Dis Ther"},{"issue":"4","key":"1064_CR32","doi-asserted-by":"publisher","first-page":"myad033","DOI":"10.1093\/mmy\/myad033","volume":"61","author":"R Pieragostini","year":"2023","unstructured":"Pieragostini R, Xhaard A, Sauvageon H, Madelaine I, Touratier S, Denis B. Context of instauration and evolution under isavuconazole, a 2-year prospective real-life study. Med Mycol. 2023;61(4):myad033. https:\/\/doi.org\/10.1093\/mmy\/myad033.","journal-title":"Med Mycol"},{"issue":"8","key":"1064_CR33","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s40265-019-01127-8","volume":"79","author":"LL Benitez","year":"2019","unstructured":"Benitez LL, Carver PL. Adverse effects associated with long-term administration of azole antifungal agents. Drugs. 2019;79(8):833\u201353.","journal-title":"Drugs"},{"issue":"3","key":"1064_CR34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/myc.12885","volume":"62","author":"F Bongomin","year":"2019","unstructured":"Bongomin F, Maguire N, Moore CB, Felton T, Rautemaa-Richardson R. Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: a retrospective comparison of rates of adverse events. Mycoses. 2019;62(3):217\u201322.","journal-title":"Mycoses"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01064-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-024-01064-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01064-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T10:09:27Z","timestamp":1732183767000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-024-01064-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1064"],"URL":"https:\/\/doi.org\/10.1007\/s40121-024-01064-4","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]},"assertion":[{"value":"7 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Carolina Garcia-Vidal has received grants and honoraria for talks from MSD, Gilead Sciences Inc., Pfizer Inc., Janssen, Novartis, Eli Lilly, Mundipharma, and Shionogi. Carolina Garcia-Vidal has also received a national research grant from the Instituto de Salud Carlos III. David A Enoch has participated in advisory boards for Mundipharma\/Napp, Pfizer Inc., and MSD and has received honoraria for consulting services to Tillots Pharmaceuticals and Pfizer Inc. Dionysios Neofytos has received research support from MSD and Pfizer Inc. and consulting fees from MSD, Pfizer Inc., Basilea, Takeda, and Gilead Sciences Inc. Katherine Houghton and Maria Jiminez are salaried employees of RTI Health Solutions. RTI Health Solutions received funding from Pfizer Inc. for the conduct of this research and medical writing services. Oliver Cornely has received consulting fees and payment or honoraria from Abbott, AbbVie, Akademie f\u00fcr Infektionsmedizin, Al-Jazeera Pharmaceuticals\/Hikma, Amedes, AstraZeneca, Aicuris, Basilia, Biocon, Cidara, Seqirus, Deutscher \u00c4rzteverlag, Gilead Sciences Inc., GSK, IQVIA, Janssen, Grupo Biotoscana\/United Medical\/Knight, Ipsen Pharma, Medscape\/WebMD, MedUpdate, MSD, Moderna, Mundipharma, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Munipharma, Noscendo, Noxxon, Octopharma, Paul-Martini-Stiftung, Pardes, Partner Therapeutics, Pfizer Inc., PSI, Sandoz, Scynexis, Seres, Shionogi, streamedup!, Touch Independent, and Vitis. OC has also participated on advisory boards for Boston Strategic Partners, Cidara, IQVIA, Janssen, MedPace, PSI, Pulmocide, Shionogi, and The Prime Meridian Group. Edward Broughton, Lili Jiang, Maria Lavinea Novis de Figueiredo Valente, and Maria Fernandez are shareholders in Pfizer Inc. Tobias Lahmer has received travel grants and lecture fees from Pfizer Inc., Gilead Sciences Inc., and MSD. Antonio Pagliuca, Beate Gruener, Raoul Herbrecht, Olivier Lortholary, and Cl\u00e9a Melenotte have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethical approval or waivers were received in each country. In France, a certificate of compliance with MR-004 was obtained. In Germany, a waiver was received from the primary site (Cologne; application number 21\u20131325). In Italy and Spain, ethics committee approval was received at the primary sites (Italy: University of Turin, Reference ID: 441\/2021; Spain: Hospital Clinic Barcelona, Reference ID: G-08431173). In the UK, ethical approval was received from the London\u2014Fulham Research Ethics Committee (Reference ID: 20\/PR\/0939).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}